Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BB

Ratings ESG MSCI

Ratings Sun Pharmaceutical Industries Ltd.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Sun Pharmaceutical Industries Ltd.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses: Sun Pharmaceutical Industries Ltd.
  • The firm trades with high earnings multiples: 35.83 times its 2026 earnings per share.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The group usually releases earnings worse than estimated.

Rating Financials

Sun Pharmaceutical Industries Ltd. SectorIndia

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Sun Pharmaceutical Industries Ltd. SectorIndia

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Sun Pharmaceutical Industries Ltd. SectorIndia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Sun Pharmaceutical Industries Ltd. SectorIndia

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Sun Pharmaceutical Industries Ltd. SectorIndia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
44.24B
BB
33.36B
BBB
29.64B
A
12.38B
A
9.76B
BB
8.33B
BB
-
7.84B -
6.79B - - - - - - -
6.67B
AA
6.18B
B
Average 16.52B
BBB
Weighted average by Cap.
BBB
See all sector ratings
  1. Stock Market
  2. Equities
  3. SUNPHARMA Stock
  4. Ratings Sun Pharmaceutical Industries Ltd.